MedTrace Logo

Chlorhydrate of Ropivacaine and Breast Cancer Surgery

NCT00370240 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2025-09-22

No results posted yet for this study

Summary

The aim of the study is to evaluate the effect of local anesthetic (chlorhydrate of ropivacaine) to prevent chronic pain after breast surgery for cancer.

Conditions

  • Breast Neoplasms
  • Pain,Postoperative

Interventions

DRUG

Chlorhydrate de Ropivacaine

The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)

OTHER

placebo

The PCB group received saline solution in equal volume.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Gustave Roussy, Cancer Campus, Grand Paris

    collaborator OTHER

  • Institut Curie

    lead OTHER

Principal Investigators

  • Aline H Albi-Feldzer, MD · Centre René Huguenin - Saint-Cloud - France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-07-31
Completion
2008-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00370240 on ClinicalTrials.gov